A Phase 3 interventional study of Evolocumab in Hypercholesterolemia, sponsored by Amgen. Completed at 126 sites in 29 countries. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2019-03-19.
Sponsored by Amgen · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies testing evolocumab in Hypercholesterolemia — 1 open to participants now, 1 under way, none of them phase 3. evolocumab · Hypercholesterolemia.
Among the 36 studies testing evolocumab in Hypercholesterolemia, this one is the 9th largest by enrollment, is one of 3 that started in 2014, is one of 22 in phase 3, and was the 22nd registered.
1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.
Browse Hypercholesterolemia studies →1 of the 36 studies testing evolocumab in Hypercholesterolemia is open now. Recruiting first, the newest first:
evolocumab: first FDA approval 2015 (REPATHA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.
This study: 18 Years to 99 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
36 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 7 · Phase 3 24 · Phase 4 7
First in 2011; this study’s year is marked. 3 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 770 is above the median of 110 across 976 interventional studies indexed under Hypercholesterolemia.
Median enrollment 308 across the 36 interventional studies. Of the 32 that completed or were terminated, 31 (97%) have results posted.
This tab as a report to print or save as PDF → With an account.
30 of 36 have an industry lead sponsor. The 6 most frequent:
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
35 studies in Hypercholesterolemia by Amgen: 1 open now, 1 under way, none of them phase 3. Of 34 finished, 30 (88%) have results posted.
Among the 35 studies in Hypercholesterolemia by Amgen, this one is the 9th largest by enrollment of the 31 interventional ones that give a count, is one of 3 that started in 2014, is one of 22 in phase 3, and was the 22nd registered.
Amgen’s Hypercholesterolemia studies by the year they started, since 2011.
None of the studies under way reaches primary completion within a year.
Among the 36 studies testing evolocumab in Hypercholesterolemia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Amgen’s 35 in Hypercholesterolemia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study was to characterize the safety and tolerability of long-term administration of evolocumab in adults with known coronary artery disease and hypercholesterolemia.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received 420 mg evolocumab once a month for up to 2 years.
Biological: Evolocumab
Administered by subcutaneous injection once a month
Also known as: AMG 145, Repatha
Number of Participants With Adverse Events
The severity of each adverse event (AE) was graded using the Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 criteria, where Grade 1 = Mild AE, Grade 2 = Moderate AE, Grade 3 = Severe or medically significant AE, Grade 4 = Life-threatening consequences, and Grade 5 = death related to AE. An adverse device effect was defined as any adverse event related to the use of a medical device (autoinjector/pen or automated mini doser \[AMD\]), including but not limited to, AEs resulting from insufficient or inadequate Instructions for Use, AEs resulting from any malfunction of the device, or AEs resulting from use error or from intentional misuse of the device.
Time frame: From first dose of evolocumab up to 30 days after the last dose, or end of study, whichever was earlier, up to 108 weeks.
Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C)
Time frame: Baseline (of study 20120153) and weeks 0, 4, 12, 24, 36, 48, 52, 76, and 104 of study 20140128
This study was conducted at 126 centers in 29 countries in the regions of Europe, North America, Asia Pacific, and Latin America. Participants were enrolled from 24 November 2014 to 31 August 2016.
| Milestone | Evolocumab |
|---|---|
| Started | 770 |
| Completed | 745 |
| Not completed | 25 |
| Withdrew: Death | 9 |
| Withdrew: Withdrawal by subject | 14 |
| Withdrew: Lost to follow-up | 2 |
The severity of each adverse event (AE) was graded using the Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 criteria, where Grade 1 = Mild AE, Grade 2 = Moderate AE, Grade 3 = Severe or medically significant AE, Grade 4 = Life-threatening consequences, and Grade 5 = death related to AE. An adverse device effect was defined as any adverse event related to the use of a medical device (autoinjector/pen or automated mini doser \[AMD\]), including but not limited to, AEs resulting from insufficient or inadequate Instructions for Use, AEs resulting from any malfunction of the device, or AEs resulting from use error or from intentional misuse of the device.
| Participants | Evolocumab |
|---|---|
| Any adverse event | 526 |
| Adverse events ≥ Grade 2 | 415 |
| Adverse events ≥ Grade 3 | 206 |
| Adverse events ≥ Grade 4 | 38 |
| Serious adverse events | 153 |
| AEs leading to discontinuation of evolocumab | 14 |
| Fatal adverse events | 6 |
| Device-related adverse events | 12 |
| Device-related adverse events ≥ Grade 2 | 2 |
| Device-related adverse events ≥ Grade 3 | 1 |
| Device-related adverse events ≥ Grade 4 | 0 |
| Serious device-related adverse events | 0 |
| percent change | Evolocumab |
|---|---|
| Percent change from baseline to week 0 | -21.52 ± 40.49 |
| Percent change from baseline to week 4 | -57.23 ± 22.19 |
| Percent change from baseline to week 12 | -58.54 ± 25.60 |
| Percent change from baseline to week 24 | -55.26 ± 28.51 |
| Percent change from baseline to week 36 | -51.72 ± 30.34 |
| Percent change from baseline to week 48 | -53.65 ± 28.72 |
| Percent change from baseline to week 52 | -51.30 ± 28.48 |
| Percent change from baseline to week 76 | -51.73 ± 32.49 |
| Percent change from baseline to week 104 | -47.94 ± 36.49 |
Collected over Total deaths are reported from the 1st dose of evolocumab up to the end of study; adverse events are reported from the 1st dose of evolocumab up to 30 days after the last dose of study drug or end of study, whichever was earlier. The median (minimum, maximum) duration of treatment was 23.7 (0.4, 24.6) months.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Evolocumab | 9/770 (1.2%) | 153/770 (19.9%) | 49/770 (6.4%) |
| Event | Evolocumab |
|---|---|
| Angina pectorisCardiac disorders | 13/770 |
| Non-cardiac chest painGeneral disorders | 6/770 |
| Angina unstableCardiac disorders | 5/770 |
| Atrial fibrillationCardiac disorders | 5/770 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 5/770 |
| Acute myocardial infarctionCardiac disorders | 4/770 |
| Coronary artery diseaseCardiac disorders | 4/770 |
| Chest painGeneral disorders | 4/770 |
| PneumoniaInfections and infestations | 4/770 |
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 4/770 |
| Event | Evolocumab |
|---|---|
| HypertensionVascular disorders | 49/770 |
All enrolled participants. Baseline is defined as parent study 20120153 baseline.
| Age, Continuous(years) | Evolocumab |
|---|---|
| Mean | 59.5 ± 8.8 |
| Age, Customized(Participants) | Evolocumab |
|---|---|
| 18 - 64 years | 536 |
| ≥ 65 years | 234 |
| Sex: Female, Male(Participants) | Evolocumab |
|---|---|
| Female | 202 |
| Male | 568 |
| Ethnicity (NIH/OMB)(Participants) | Evolocumab |
|---|---|
| Hispanic or Latino | 38 |
| Not Hispanic or Latino | 732 |
| Unknown or Not Reported | 0 |
| Race/Ethnicity, Customized(Participants) | Evolocumab |
|---|---|
| American Indian or Alaska Native | 1 |
| Asian | 19 |
| Black or African American | 5 |
| Native Hawaiian or Other Pacific Islander | 1 |
| White | 729 |
| Multiple | 11 |
| Other | 4 |
| Low-density Lipoprotein Cholesterol (LDL-C) Concentration(mg/dL) | Evolocumab |
|---|---|
| Mean | 92.2 ± 27.3 |
Showing the first 100 of 126 sites across 29 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Nov 2014 to primary completion in Mar 2018, 39 months.
Results were first posted in Mar 2019, 1 year after primary completion.
Of 122 industry-sponsored phase 3 interventional studies under Hypercholesterolemia, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 39 months is above that.
Counting every sponsor, half of 125 studies reached it within 18 months; a quarter within 10 and three quarters within 27.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Evolocumab